eblasakimab
aslan
['derm', 'eblasakimab', 'imab ']
today, aslan announced the presentation of new eblasakimab data at the 2022 european academy of dermatology and venereology (eadv) annual congress in milan, italy. 
We are a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.